Knight Therapeutics Inc. (TSX:GUD)

Market Cap	582.77M
Revenue (ttm)	372.78M
Net Income (ttm)	11.06M
Shares Out	99.45M
EPS (ttm)	0.10
PE Ratio	58.66
Forward PE	80.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,429
Average Volume	42,069
Open	5.73
Previous Close	5.71
Day's Range	5.73 - 5.88
52-Week Range	5.09 - 6.45
Beta	0.17
RSI	48.59
Earnings Date	May 8, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD